A global healthcare company that specializes in plasma-related medicines has a global presence in the US, Europe, and Asia. The firm’s external innovation arm seeks to partner with early-stage companies developing therapeutic assets that strategically align with the firm’s focus areas. The group is science-focused and strategically invests in the corporation’s long-term goal of developing pipelines in biotech beyond plasma-related medicines. The group primarily makes equity investments but is open to different structures such as co-development, licensing, and potentially acquisitions. The group often co-invests/syndicates with other investors and typically does not require a board seat. The group is open to considering global opportunities with a focus on the US and Europe.
The group is focused on therapeutics and is not interested in diagnostics or other sectors. The group seeks strategic alignments within the parent company’s pharma business, which focuses on immunology, infectious diseases, pulmonology, and hematology. The group is particularly interested in biologics due to their expertise in this class of assets and is open to considering other classes of assets such as small molecules, cell and gene therapy (platform), mRNA therapies, etc. The group is also open to considering orphan diseases as well. In terms of phases of development, the group is interested in pre-clinical to early clinical phases.
The group does not have any specific requirements for the company’s management team. The group acts as an active investor and is open to working with portfolio companies with their in-house expertise and leveraging the firm’s manufacturing capabilities.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment